Approved accessible "lanadelumab-flyo injection"

In the United States, lanadelumab is indicated for the prophylaxis of hereditary angioedema (HAE) attacks. Lanadelumab, sold under the brand name Takhzyro, is a human monoclonal antibody (class IgG1 kappa)[6] that targets plasma kallikrein (pKal) in order to promote prevention of angioedema in people with hereditary angioedema. Lanadelumab, was approved in the United States as the first monoclonal antibody indicated for prophylactic treatment to prevent hereditary angioedema (HAE) attacks. Lanadelumab is the first treatment for hereditary angioedema (HEA) prevention made by using cells within a lab, not human plasma.

The US Food and Drug Administration (FDA) approved the use of lanadelumab in August 2018, for people that are 12 years and older and have either type I or type II hereditary angioedema (HEA).

How can 1 go about obtaining lanadelumab-flyo injection?

If lanadelumab-flyo injection are not yet approved or available in your area, you may request its price in India under a specific brand name through IPN. For assistance and guidance, you can contact us by providing complete details. Our pharmaceutical expert will help you find a suitable and practical solution to your query. To receive comprehensive support, please call us at +91 9891 296 838 (Mr. Tarun) / +91 9811 747 774 (Mr. Neeraj).

TAKHZYRO (lanadelumab-flyo) injection, for subcutaneous use. Initial U.S. Approval: YYYY.

References

• Summary of Product Characteristics [FDA]: Takhzyro (lanadelumab) [PDF] Dyax Corp., August 2018.
• Summary of Product Characteristics [EMA]: Takhzyro (lanadelumab) [PDF] Shire Pharmaceuticals Ireland Ltd, November 2018.
• EMA Human Medicines: Takhzyro (lanadelumab) 17/12/2018, cited on: 22/02/2019.